New combo therapy aims to fight HPV head and neck cancer
NCT ID NCT07172256
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 pilot study is testing a new drug called CUE-101, alone or combined with pembrolizumab, in 30 people with newly diagnosed, locally advanced HPV-16 head and neck cancer. The goal is to see if the combination boosts the immune system's ability to fight the cancer before standard treatment. Researchers will measure immune cell levels and monitor safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CUE-101 and pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with HPV-related head and neck cancer, potentially improving outcomes without the need for lifelong medication.
What could go wrong
This is a small, early-phase pilot study with only 30 participants, so results may not apply to everyone. The treatment may cause side effects or may not work better than existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact